Table 2.
Percentage of antimicrobial susceptibility in ESBL-producing E. coli strains based on MIC results.
| Antimicrobial agents | R (%) | I (%) | S (%) |
CLSI breakpoints (µg/mL) |
|
|---|---|---|---|---|---|
| S | R | ||||
| Cephalosporins | |||||
| Cefepime | 67 | 13 | 20 | ≤8 | ≥32 |
| Cefixime | 99 | 0 | 1 | ≤0.25 | ≥1 |
| Ceftriaxone | 28 | 42 | 30 | ≤8 | ≥64 |
| Ceftazidime | 19 | 26 | 55 | ≤16 | ≥32 |
| Ceftizoxime | 46 | 27 | 27 | ≤8 | ≥64 |
| Cefotaxime | 13 | 40 | 47 | ≤8 | ≥64 |
| Carbapenems | |||||
| Imipenem | 23 | 11 | 66 | ≤4 | ≥16 |
| Meropenem | 18 | 15 | 67 | ≤4 | ≥16 |
| Aminoglycosides | |||||
| Amikacin | 34 | 8 | 58 | ≤16 | ≥64 |
| Gentamicin | 37 | 12 | 51 | ≤4 | ≥16 |
| Others | |||||
| Ciprofloxacin | 76 | 0 | 24 | ≤1 | ≥4 |
| Colistin | 82 | 0 | 18 | ≤2 | ≥4 |
| Trimethoprim/sulfamethoxazole | 65 | 7 | 28 | ≤2/38 | ≥4/76 |
| Piperacillin/tazobactam | 20 | 38 | 42 | ≤16/4 | ≥128/4 |
R: resistance, I: intermediate, S: sensitive, CLSI: Clinical Laboratory Standards Institute, and ESBL: extended-spectrum beta-lactamase.